|
2024-02-20 |
2024-02-16 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
3,010
-3.6%
15.62
USD 47,009
|
3,010
-3.6%
|
15.62
|
USD 47,009
|
|
|
2024-02-20 |
2024-02-16 |
S
Sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
2,615
-2.3%
15.62
USD 40,840
|
2,615
-2.3%
|
15.62
|
USD 40,840
|
|
|
2024-02-20 |
2024-02-16 |
S
Sale
|
Pitman Jama
SVP, Chief Development Officer
Officer
|
2,267
-3.2%
15.62
USD 35,405
|
2,267
-3.2%
|
15.62
|
USD 35,405
|
|
|
2024-02-20 |
2024-02-16 |
S
Sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
2,267
-4.0%
15.62
USD 35,405
|
2,267
-4.0%
|
15.62
|
USD 35,405
|
|
|
2024-01-18 |
2024-01-16 |
S
Sale
|
Pitman Jama
SVP, Chief Development Officer
Officer
|
1,624
-3.1%
14.47
USD 23,499
|
1,624
-3.1%
|
14.47
|
USD 23,499
|
|
|
2024-01-18 |
2024-01-16 |
S
Sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
2,435
-2.5%
14.47
USD 35,234
|
2,435
-2.5%
|
14.47
|
USD 35,234
|
|
|
2024-01-18 |
2024-01-16 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
2,435
-3.6%
14.47
USD 35,234
|
2,435
-3.6%
|
14.47
|
USD 35,234
|
|
|
2024-01-18 |
2024-01-16 |
S
Sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
1,624
-3.3%
14.47
USD 23,499
|
1,624
-3.3%
|
14.47
|
USD 23,499
|
|
|
2023-12-14 |
2023-12-13 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
2,792
-3.9%
15.37
USD 42,905
|
2,792
-3.9%
|
15.37
|
USD 42,905
|
|
|
2023-12-14 |
2023-12-13 |
S
Sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
2,792
-2.8%
15.37
USD 42,905
|
2,792
-2.8%
|
15.37
|
USD 42,905
|
|
|
2023-12-14 |
2023-12-13 |
S
Sale
|
Pitman Jama
See Remarks
Officer
|
1,662
-3.1%
15.37
USD 25,540
|
1,662
-3.1%
|
15.37
|
USD 25,540
|
|
|
2023-12-14 |
2023-12-13 |
S
Sale
|
Hoerter Steven L.
President and CEO
Executive Director
|
30,664
-29.6%
15.37
USD 471,217
|
30,664
-29.6%
|
15.37
|
USD 471,217
|
|
|
2023-12-14 |
2023-12-13 |
S
Sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
1,727
-3.4%
15.37
USD 26,539
|
1,727
-3.4%
|
15.37
|
USD 26,539
|
|
|
2023-12-01 |
2023-11-30 |
PS
Planned sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
17,801
-28.2%
12.57
USD 223,755
|
17,801
-28.2%
|
12.57
|
USD 223,755
|
|
|
2023-10-31 |
2023-10-30 |
S
Sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
1,407
-2.2%
12.02
USD 16,909
|
1,407
-2.2%
|
12.02
|
USD 16,909
|
|
|
2023-10-31 |
2023-10-30 |
S
Sale
|
Hoerter Steven L.
President and CEO
Executive Director
|
21,573
-34.5%
12.02
USD 259,256
|
21,573
-34.5%
|
12.02
|
USD 259,256
|
|
|
2023-10-31 |
2023-10-30 |
S
Sale
|
Pitman Jama
See Remarks
Officer
|
1,407
-2.8%
12.02
USD 16,909
|
1,407
-2.8%
|
12.02
|
USD 16,909
|
|
|
2023-10-31 |
2023-10-30 |
S
Sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
2,360
-2.5%
12.02
USD 28,362
|
2,360
-2.5%
|
12.02
|
USD 28,362
|
|
|
2023-10-31 |
2023-10-30 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
2,316
-3.5%
12.02
USD 27,833
|
2,316
-3.5%
|
12.02
|
USD 27,833
|
|
|
2023-10-04 |
2023-10-02 |
S
Sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
2,942
-3.4%
12.68
USD 37,305
|
2,942
-3.4%
|
12.68
|
USD 37,305
|
|
|
2023-06-21 |
2023-06-16 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
1,655
-2.8%
14.40
USD 23,835
|
1,655
-2.8%
|
14.40
|
USD 23,835
|
|
|
2023-06-21 |
2023-06-16 |
PS
Planned sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
1,238
-2.1%
14.40
USD 17,829
|
1,238
-2.1%
|
14.40
|
USD 17,829
|
|
|
2023-06-21 |
2023-06-16 |
PS
Planned sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
1,655
-1.9%
14.40
USD 23,835
|
1,655
-1.9%
|
14.40
|
USD 23,835
|
|
|
2023-06-21 |
2023-06-16 |
S
Sale
|
Flynn Daniel Lee
Chief Scientific Officer
Officer
|
1,655
-2.8%
14.40
USD 23,835
|
1,655
-2.8%
|
14.40
|
USD 23,835
|
|
|
2023-06-21 |
2023-06-16 |
S
Sale
|
Pitman Jama
See Remarks
Officer
|
1,238
-2.7%
14.40
USD 17,829
|
1,238
-2.7%
|
14.40
|
USD 17,829
|
|
|
2023-06-12 |
2023-06-08 |
B
Purchase
|
Friedman Franklin Stuart
Non-Executive Director
|
10,000
+inf%
13.88
USD 138,828
|
10,000
+inf%
|
13.88
|
USD 138,828
|
|
|
2023-05-12 |
2023-05-10 |
B
Purchase
|
Walsh Dennis Leo
Non-Executive Director
|
11,000
+inf%
13.86
USD 152,416
|
11,000
+inf%
|
13.86
|
USD 152,416
|
|
|
2023-03-23 |
2023-03-21 |
PS
Planned sale
|
Hoerter Steven L.
President and CEO
Executive Director
|
7,500
-100.0%
15.57
USD 116,782
|
7,500
-100.0%
|
15.57
|
USD 116,782
|
|
|
2023-02-17 |
2023-02-16 |
S
Sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
1,159
-1.9%
15.10
USD 17,500
|
1,159
-1.9%
|
15.10
|
USD 17,500
|
|
|
2023-02-17 |
2023-02-16 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
1,370
-2.3%
15.10
USD 20,686
|
1,370
-2.3%
|
15.10
|
USD 20,686
|
|
|
2023-02-17 |
2023-02-16 |
S
Sale
|
Flynn Daniel Lee
Chief Scientific Officer
Officer
|
1,370
-2.3%
15.10
USD 20,686
|
1,370
-2.3%
|
15.10
|
USD 20,686
|
|
|
2023-02-17 |
2023-02-16 |
S
Sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
971
-1.1%
15.10
USD 14,661
|
971
-1.1%
|
15.10
|
USD 14,661
|
|
|
2023-02-17 |
2023-02-16 |
S
Sale
|
Pitman Jama
See Remarks
Officer
|
1,159
-2.5%
15.10
USD 17,500
|
1,159
-2.5%
|
15.10
|
USD 17,500
|
|
|
2023-02-16 |
2023-02-14 |
PS
Planned sale
|
Hoerter Steven L.
President and CEO
Executive Director
|
30,045
-80.0%
16.00
USD 480,720
|
30,045
-80.0%
|
16.00
|
USD 480,720
|
|
|
2023-01-24 |
2023-01-24 |
B
Purchase
|
Brightstar Associates LLC
Large shareholder
|
1,666,666
+9.2%
18.00
USD 29,999,988
|
1,666,666
+9.2%
|
18.00
|
USD 29,999,988
|
|
|
2023-01-19 |
2023-01-17 |
PS
Planned sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
2,403
-3.2%
21.24
USD 51,043
|
2,403
-3.2%
|
21.24
|
USD 51,043
|
|
|
2023-01-19 |
2023-01-17 |
PS
Planned sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
1,603
-3.2%
21.24
USD 34,050
|
1,603
-3.2%
|
21.24
|
USD 34,050
|
|
|
2023-01-19 |
2023-01-17 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
2,403
-5.2%
21.24
USD 51,043
|
2,403
-5.2%
|
21.24
|
USD 51,043
|
|
|
2023-01-19 |
2023-01-17 |
S
Sale
|
Pitman Jama
See Remarks
Officer
|
1,603
-4.4%
21.24
USD 34,050
|
1,603
-4.4%
|
21.24
|
USD 34,050
|
|
|
2023-01-19 |
2023-01-17 |
S
Sale
|
Flynn Daniel Lee
Chief Scientific Officer
Officer
|
2,403
-5.2%
21.24
USD 51,043
|
2,403
-5.2%
|
21.24
|
USD 51,043
|
|
|
2022-10-05 |
2022-10-03 |
S
Sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
2,587
-3.4%
18.73
USD 48,455
|
2,587
-3.4%
|
18.73
|
USD 48,455
|
|
|
2022-06-21 |
2022-06-16 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
1,768
-3.7%
10.75
USD 19,006
|
1,768
-3.7%
|
10.75
|
USD 19,006
|
|
|
2022-06-21 |
2022-06-16 |
S
Sale
|
Flynn Daniel Lee
Chief Scientific Officer
Officer
|
1,768
-3.7%
10.75
USD 19,006
|
1,768
-3.7%
|
10.75
|
USD 19,006
|
|
|
2022-06-21 |
2022-06-16 |
PS
Planned sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
1,768
-2.2%
10.75
USD 19,006
|
1,768
-2.2%
|
10.75
|
USD 19,006
|
|
|
2022-06-21 |
2022-06-16 |
PS
Planned sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
1,311
-2.6%
10.75
USD 14,093
|
1,311
-2.6%
|
10.75
|
USD 14,093
|
|
|
2022-06-21 |
2022-06-16 |
S
Sale
|
Pitman Jama
See Remarks
Officer
|
1,298
-3.4%
10.75
USD 13,954
|
1,298
-3.4%
|
10.75
|
USD 13,954
|
|
|
2022-04-29 |
2022-04-29 |
B
Purchase
|
Brightstar Associates LLC
Large shareholder
|
1,478,978
+8.9%
10.00
USD 14,789,780
|
1,478,978
+8.9%
|
10.00
|
USD 14,789,780
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
984
-1.3%
9.05
USD 8,905
|
984
-1.3%
|
9.05
|
USD 8,905
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
Martin Daniel C.
Chief Commercial Officer
Officer
|
1,146
-2.3%
9.05
USD 10,371
|
1,146
-2.3%
|
9.05
|
USD 10,371
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
Flynn Daniel Lee
Chief Scientific Officer
Officer
|
1,366
-2.8%
9.05
USD 12,362
|
1,366
-2.8%
|
9.05
|
USD 12,362
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
1,368
-2.8%
9.05
USD 12,380
|
1,368
-2.8%
|
9.05
|
USD 12,380
|
|
|
2022-02-18 |
2022-02-16 |
S
Sale
|
Pitman Jama
See Remarks
Officer
|
1,146
-2.9%
9.05
USD 10,371
|
1,146
-2.9%
|
9.05
|
USD 10,371
|
|
|
2021-10-06 |
2021-10-04 |
PS
Planned sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
2,659
-5.5%
33.17
USD 88,199
|
2,659
-5.5%
|
33.17
|
USD 88,199
|
|
|
2021-05-05 |
2021-05-03 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
300
-100.0%
46.75
USD 14,025
|
300
-100.0%
|
46.75
|
USD 14,025
|
|
|
2021-05-05 |
2021-05-03 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
7,700
-96.2%
46.07
USD 354,718
|
7,700
-96.2%
|
46.07
|
USD 354,718
|
|
|
2021-04-21 |
2021-04-20 |
PS
Planned sale
|
Bristol James Arthur
Non-Executive Director
|
1,700
-100.0%
45.60
USD 77,514
|
1,700
-100.0%
|
45.60
|
USD 77,514
|
|
|
2021-04-21 |
2021-04-19 |
PS
Planned sale
|
Bristol James Arthur
Non-Executive Director
|
1,300
-100.0%
46.66
USD 60,662
|
1,300
-100.0%
|
46.66
|
USD 60,662
|
|
|
2021-04-21 |
2021-04-19 |
PS
Planned sale
|
Bristol James Arthur
Non-Executive Director
|
4,000
-75.5%
46.13
USD 184,518
|
4,000
-75.5%
|
46.13
|
USD 184,518
|
|
|
2021-04-14 |
2021-04-12 |
PS
Planned sale
|
Bristol James Arthur
Non-Executive Director
|
5,217
-100.0%
44.09
USD 230,040
|
5,217
-100.0%
|
44.09
|
USD 230,040
|
|
|
2021-04-14 |
2021-04-12 |
PS
Planned sale
|
Bristol James Arthur
Non-Executive Director
|
9,483
-64.5%
43.70
USD 414,370
|
9,483
-64.5%
|
43.70
|
USD 414,370
|
|
|
2021-04-06 |
2021-04-01 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
906
-100.0%
46.72
USD 42,328
|
906
-100.0%
|
46.72
|
USD 42,328
|
|
|
2021-04-06 |
2021-04-01 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
4,994
-84.6%
45.69
USD 228,169
|
4,994
-84.6%
|
45.69
|
USD 228,169
|
|
|
2021-04-06 |
2021-04-01 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
2,100
-26.2%
44.80
USD 94,074
|
2,100
-26.2%
|
44.80
|
USD 94,074
|
|
|
2021-03-03 |
2021-03-01 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
1,104
-100.0%
44.68
USD 49,324
|
1,104
-100.0%
|
44.68
|
USD 49,324
|
|
|
2021-03-03 |
2021-03-01 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
6,896
-86.2%
43.94
USD 302,983
|
6,896
-86.2%
|
43.94
|
USD 302,983
|
|
|
2021-02-18 |
2021-02-16 |
S
Sale
|
Sherman Matthew L
EVP & Chief Medical Officer
Officer
|
132
-0.4%
48.87
USD 6,451
|
132
-0.4%
|
48.87
|
USD 6,451
|
|
|
2021-02-18 |
2021-02-16 |
S
Sale
|
Flynn Daniel Lee
Chief Scientific Officer
Officer
|
508
-7.2%
48.87
USD 24,826
|
508
-7.2%
|
48.87
|
USD 24,826
|
|
|
2021-02-18 |
2021-02-16 |
S
Sale
|
Kelly Thomas Patrick
Chief Financial Officer
Officer
|
524
-7.4%
48.87
USD 25,608
|
524
-7.4%
|
48.87
|
USD 25,608
|
|
|
2021-02-03 |
2021-02-01 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
800
-100.0%
45.96
USD 36,770
|
800
-100.0%
|
45.96
|
USD 36,770
|
|
|
2021-02-03 |
2021-02-01 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
4,518
-85.0%
45.64
USD 206,188
|
4,518
-85.0%
|
45.64
|
USD 206,188
|
|
|
2021-02-03 |
2021-02-01 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
2,682
-33.5%
44.34
USD 118,915
|
2,682
-33.5%
|
44.34
|
USD 118,915
|
|
|
2021-01-20 |
2021-01-15 |
PS
Planned sale
|
Bristol James Arthur
Non-Executive Director
|
600
-100.0%
51.11
USD 30,666
|
600
-100.0%
|
51.11
|
USD 30,666
|
|
|
2021-01-20 |
2021-01-15 |
PS
Planned sale
|
Bristol James Arthur
Non-Executive Director
|
6,400
-91.4%
50.21
USD 321,373
|
6,400
-91.4%
|
50.21
|
USD 321,373
|
|
|
2021-01-06 |
2021-01-04 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
2,794
-100.0%
57.37
USD 160,294
|
2,794
-100.0%
|
57.37
|
USD 160,294
|
|
|
2021-01-06 |
2021-01-04 |
PS
Planned sale
|
Taylor Michael Douglas
Non-Executive Director
|
8,517
-75.3%
56.73
USD 483,175
|
8,517
-75.3%
|
56.73
|
USD 483,175
|
|
